CSIMarket



Kymera Therapeutics Inc.  (KYMR)
Other Ticker:  
 

Cumulative Kymera Therapeutics's Working Capital Ratio for Trailing Twelve Months Period

KYMR's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

KYMR Working Capital Ratio for Trailing Twelve Months Period

(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
Y / Y Current Liabilities Growth 27.15 % 61.58 % 107.77 % - -
Y / Y Current Assets Growth 18.19 % 42.68 % 82.85 % - -
Working Capital Ratio for Trailing Twelve Months Period 18.17 18.53 19.02 18.97 20.52
Total Ranking # 1176 # 1357 # # 1235 # 1515
Seq. Current Liabilities Growth 1.94 % -2.87 % 7.27 % 19.72 % 29.54 %
Seq. Current Assets Growth -6.63 % -20.66 % 49.05 % 7.05 % 12.72 %


Working Capital Ratio for Trailing Twelve Months Period Comment
On the trailing twelve months basis Due to rise in Current Liabilities in the II. Quarter to $24 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 18.17 below Kymera Therapeutics Inc. average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 154 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Kymera Therapeutics. While Working Capital Ratio for Trailing Twelve Months Period overall ranking has improved so far to 1176, from total ranking in previous quarter at 1357.

What is Working Capital Ratio?
More about KYMR
Working Capital Ratio KYMR in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 155
Sector # 537
S&P 500 # 1163


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
4.6 3.65 2.83
(Jun 30 2022)   (Mar 31 2021)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Jun 30 2022, within Biotechnology & Pharmaceuticals Industry Working Capital Ratio for Trailing Twelve Months Period
Pharmacyte Biotech Inc.  49.81 
Singular Genomics Systems Inc.  44.60 
Cabaletta Bio Inc.  42.07 
Skinovation Pharmaceutical Incorporated  38.69 
Acumen Pharmaceuticals Inc.  37.88 
Talaris Therapeutics Inc.  36.12 
Athira Pharma Inc.  36.02 
Organovo Holdings Inc.  30.23 
Protara Therapeutics Inc.  29.58 
Cardiff Oncology inc   29.05 
Cocrystal Pharma Inc.  27.48 
Relay Therapeutics Inc.  27.22 
Miromatrix Medical Inc   27.16 
Vor Biopharma Inc.  25.96 
Monte Rosa Therapeutics Inc.  25.64 
Replimune Group Inc.  24.82 
Freeline Therapeutics Holdings Plc  24.73 
Aura Biosciences Inc.  24.71 
Fusion Pharmaceuticals Inc.  23.46 
Citius Pharmaceuticals Inc.  21.98 
Rubius Therapeutics Inc.  21.97 
Lixte Biotechnology Holdings Inc.  21.42 
Crispr Therapeutics Ag  21.17 
Strongbridge Biopharma plc  21.15 
Acasti Pharma Inc.  20.97 
Dyne Therapeutics Inc.  20.97 
4d Molecular Therapeutics Inc.  19.97 
Icosavax Inc.  19.82 
Vicarious Surgical Inc.  19.72 
Salarius Pharmaceuticals inc.  18.84 


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

VYNT's Profile

Stock Price

VYNT's Financials

Business Description

Fundamentals

Charts & Quotes

VYNT's News

Suppliers

VYNT's Competitors

Customers & Markets

Economic Indicators

VYNT's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright Š 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071